(Reuters) -Invitae Corp said on Monday a group of investors including SoftBank Group Corp will invest $1.15 billion in the U.S. genetic diagnostics company.
It said the investment, to be used for its growth initiatives, will be in convertible senior notes, which will bear 1.5% interest per year.
The company said the notes will have an initial conversion price of $43.18 per share of its common stock, representing a premium of 10.2% to Invitae’s closing price on Friday.
Earlier this year, SoftBank invested $900 million in gene sequencing firm Pacific Biosciences of California Inc.
San Francisco-based Invitae offers genetic testing services for a range of diseases, including skin and eye conditions, cancers as well as reproductive health in and outside the United States.
Shares of the company, which started operations in 2010, have more than tripled in the past twelve months, giving it a market valuation of $7.7 billion.
J. Wood Capital Advisors LLC and Perella Weinberg Partners LP were financial advisers to Invitae on the transaction.
Reporting by Amruta Khandekar in Bengaluru; Editing by Shinjini Ganguli
Our Standards: The Thomson Reuters Trust Principles.
After years of material science breakthroughs, a team proved that a rugged, sea-ready composite could…
TAHO, a Venice-based compute startup founded by ex-Meta and Google engineers, raised $3.5 million in…
The 9th Future Investment Initiative in Riyadh spotlighted how AI is rapidly redefining global growth,…
Onward Robotics has appointed Brendon Bielat as Chief Product Officer, strengthening its leadership team as…
Dubai, UAE, 12th December, 2025: The Fédération Internationale de l’Automobile (FIA), the global governing body for motor sport…
FIA President Mohammed Ben Sulayem says new agreement secures the FIA Formula One World Championship’s…